Physician profile
Shing Li
NPI 1184945552
$3,953.54
in general payments reported to CMS, 2019-2025
32 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $327 · 2021: $565 · 2022: $514 · 2023: $397 · 2024: $830 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,710 · Education: $17.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.04 |
| Education | $17.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $435.83 | 2019-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $419.43 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $398.57 | 2019-2025 | Jynarque |
| Novo Nordisk INC | $368.32 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $247.40 | 2019-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $209.87 | 2019-2025 | |
| Lilly USA, LLC | $175.36 | 2019-2025 | Jardiance |
| Pfizer INC. | $173.18 | 2019-2024 | |
| Calliditas Therapeutics US INC. | $162.58 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $134.73 | 2021-2025 | Acthar |
| Travere Therapeutics, INC. | $132.23 | 2024-2025 | Filspari |
| Akebia Therapeutics INC | $127.07 | 2019-2021 | |
| Ardelyx, INC. | $115.18 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $91.28 | 2022-2023 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $87.42 | 2020-2023 | Veltassa, Korsuva |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $83.76 | 2019-2024 | Gattex |
| Merck Sharp & Dohme LLC | $72.36 | 2019-2021 | |
| Kaleo, INC. | $68.00 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $66.31 | 2021-2022 | |
| Exact Sciences Corporation | $64.86 | 2023-2024 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $56.66 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $48.82 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $33.99 | 2021-2024 | Gvoke Hypopen |
| Scpharmaceuticals INC. | $32.86 | 2025 | |
| Opko Pharmaceuticals, LLC | $25.89 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $25.85 | 2021 | |
| Nxstage Medical, INC. | $22.92 | 2022 | |
| Fresenius USA Marketing, INC. | $21.07 | 2024 | Velphoro |
| Sanofi-Aventis U.S. LLC | $14.54 | 2020 | |
| Glaxosmithkline, LLC. | $13.40 | 2019 | |
| Amarin Pharma, INC. | $12.50 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shing Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.